PHA Canada is committed to ensuring that all PH patients have access to the best possible care and treatment at diagnosis and beyond. We work to empower and support patients, caregivers, family, and friends—along with members of the PH medical community—to advocate to federal, provincial, and territorial governments on issues that are important to our community. Your support helps our voice be heard.
Since June 2015, PHA Canada has been advocating for publicly funded access to all Health Canada-approved treatments for PAH. We continue to be concerned about disparities that exist in the quality of care PAH patients may receive depending on what province or territory they live in or whether they have private insurance.
We are very proud of the progress that’s been made in ensuring PAH patients have access to all Health Canada-approved treatments, including Opsumit® (macitentan), Uptravi® (selexipeg), and Adempas® (riociguat). In 2018, we saw Uptravi added to public drug plans across the country. In 2020, the pan-Canadian Pharmaceutical Alliance (pCPA) successfully concluded pricing negotiations for Opsumit. And by the end of 2022, public funding for Opsumit had expanded across most of the country.
But gaps remain. British Columbia is now the only province to refuse to provide Opsumit® as a treatment option to PAH patients in need. And Adempas remains available through private insurance only.
If you are a patient or a caregiver who would like to educate elected officials in your province about the importance of access to personalized treatment for PAH, please click here to contact us today.
Check out Take Action PAH for campaign updates and more information on how to get involved.